Skip to main content

Advertisement

Table 1 Number (proportion) of trials categorised as suspected marketing trials by journal following the consensus meeting

From: Characterisation of trials where marketing purposes have been influential in study design: a descriptive study

  YES MAYBE NO Total number of eligible trials (%)
Annals of Internal Medicine 1 0 4 5 (3)
The BMJ 0 0 15 15 (8)
JAMA 1 1 18 20 (10)
Lancet 18 4 36 58 (30)
NEJM 21 9 62 92 (47)
PLOS Medicine 0 0 4 4 (2)
Total 41 (21) 14 (7) 139 (72) 194